X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Sunshine Guojian received an exclusive license to develop and commercialize a select number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau.
Lead Product(s): Anti-VSIG4 antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Verseau Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2020
Details:
Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.
Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: SEL-212
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
